• FMC Corporation reported past second-quarter 2026 results with sales falling to US$867.1 million from US$1,050.5 million and swinging from a US$66.7 million profit to a US$186.6 million net loss, while also issuing softer full-year 2026 revenue guidance of US$3.50 billion to US$3.70 billion.
• Despite the weaker performance and outlook, FMC kept its regular quarterly dividend at US$0.08 per share and highlighted stronger adjusted EBITDA and ongoing cost and portfolio actions aimed at improving efficiency and repositioning the business.
• With FMC cutting its full-year 2026 revenue outlook amid pricing and demand pressure, we’ll now examine how this reshapes its investment narrative.

Find 55 companies with promising cash flow potential yet trading below their fair value.

FMC Investment Narrative Recap

To stay invested in FMC today, you need to believe the company can turn current losses and softer 2026 revenue guidance into a more resilient, higher-quality crop protection business through cost cuts, portfolio shifts, and new product uptake. The most important near term catalyst is execution on those efficiency and innovation plans, while the biggest risk is that ongoing pricing and demand pressure keep margins weak for longer. This latest quarter reinforces that risk, but does not clearly change it.

Against that backdrop, the decision to affirm the regular US$0.08 quarterly dividend stands out. Maintaining the payout, even after a US$186.6 million second quarter net loss and lower full year revenue outlook of US$3.50 billion to US$3.70 billion, puts more attention on cash generation, leverage and balance sheet flexibility. For investors focused on catalysts, dividend stability now has to be weighed against FMC’s elevated net debt and continued negative earnings.

Yet investors should also be aware that the real pressure point could be sustained product pricing declines and what that means for FMC’s ability to...

FMC's narrative projects $4.0 billion revenue and $296.4 million earnings by 2029.

Uncover how FMC's forecasts yield a $15.84 fair value, a 48% upside to its current price.

Exploring Other Perspectives

Before this earnings miss, the most optimistic analysts were assuming FMC could grow revenue to about US$4.3 billion and lift earnings to roughly US$488 million by 2029, a far more upbeat path than the current loss making reality, so it is worth thinking about how much those expectations and the assumed strength of new products like Isoflex might change after this update.

Explore 5 other fair value estimates on FMC - why the stock might be worth just $12.00!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your FMC research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free FMC research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate FMC's overall financial health at a glance.

Contemplating Other Strategies?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• AI is about to change healthcare. These 41 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Uncover the next big thing with 21 elite penny stocks that balance risk and reward.
• Capitalize on the AI infrastructure supercycle with our selection of the 57 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.